Sign in
CompletedPhase 2/3

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
150 people enrolled
Started
15 Nov 2022
Ended
25 Jan 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Allopurinol 300 MG
  • Atorvastatin 20mg
  • Placebo
Record updated
11 August 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Inclusion Criteria
  • Age 18 to 75 years old
  • Both sex
  • Adults with cirrhosis in a stable conditions

Who cannot take part

  • Active GIT hemorrhage
  • Renal insufficiency (serum creatinine > 2.0 mg/dl)
  • Exclusion criteria
  • Active SBP

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.

The 3 groups in the trial

  • PLACEBOPlacebo, for comparison

    Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS

  • AllopurinolExisting treatment, for comparison

    Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months

    Treatment: Allopurinol 300 MG

  • SimvastatinExisting treatment, for comparison

    Group 3: (atorvastatin n=50) who will receive oral atorvastatin 20 mg daily for 6 months

    Treatment: Atorvastatin 20mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Potential Role of Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis: A Quadruple Blind Clinical Study
Record updated
11 August 2026